TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00836602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-779788
Description: Oral Solution, Oral, 1 mg, Once daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-779788
Description: Oral Solution, Oral, 2 mg, Once daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-779788
Description: Oral Solution, Oral, \<= 4 mg, Once daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once daily, 7 days
Study: NCT04211415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks
Study: NCT03113214

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 2
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 3
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 4
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 5
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy 6
Description: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
Study: NCT04335695

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vascular Rehabilitation
Description: Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
Study: NCT00689520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin
Description: tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
Study: NCT04211415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2741a
Description: Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single, subcutaneous injection administered weekly for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single, subcutaneous injection administered weekly for 4 weeks
Study: NCT00689520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acenocoumarol
Description: tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
Study: NCT01988883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Locking gelatin capsules filled with microcrystalline cellulose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Locking gelatin capsules filled with microcrystalline cellulose
Study: NCT01654445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
Study: NCT01988883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Locking gelatin capsules filled with microcrystalline cellulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
Study: NCT04312971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Increase infusion rate
Description: Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Increase infusion rate
Description: Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decrease infusion rate
Description: Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Decrease infusion rate
Description: Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
Study: NCT02775214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy
Study: NCT03135821

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: TCM

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCM
Study: NCT00855283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN NEO
Description: 40 mg Neostigmine via intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN NEO
Description: 60 mg Neostigmine via intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN NEO + IN Glycopyrrolate
Description: Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Visit
Description: 2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
Study: NCT00712010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein native
Description: Whey protein native against the 6 other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein native
Description: Whey protein native against the 6 other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein native
Description: Whey protein native against the 6 other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein native
Description: Whey protein native against the 6 other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein native
Description: Whey protein native against the 6 other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein native
Description: Whey protein native against the 6 other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein microgels
Description: Whey protein microgels versus the six other arms
Study: NCT00085930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBV specific CTLs
Description: CTLs: 2x10e7 cells/m2
Study: NCT00560651

Intervention type: PROCEDURE
Intervention: CCL (Corneal Cross Linking)
Description: Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
Study: NCT03071406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg/dose IV q6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg/dose IV q6 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
Study: NCT02636257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recessive Spherical Headed Silicone Intubation
Description: Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dacryocystorhinostomy
Description: Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
Study: NCT01316770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Parotid Irrigation
Description: Irrigation of the parotid gland from one side of the mouth with dexamethasone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Parotid Irrigation
Description: Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
Study: NCT00622843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal conjugate vaccine
Description: Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal polysaccharide vaccine
Description: PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal polysaccharide vaccine
Description: PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
Study: NCT01015976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: Roux en Y bariatric surgery

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No surgery
Study: NCT01933880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
Description: Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
Study: NCT02645084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offering an online risk assessment questionnaire
Description: Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
Study: NCT02244164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretinomimetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretinomimetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitors
Study: NCT01588171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin
Description: Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
Study: NCT02789475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin administration
Study: NCT01768208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study: NCT01021592

Intervention type: DRUG
Intervention: bortezomib
Description: Injection into a vein 1.3 mg/m2 twice a week for 21 days
Study: NCT04450186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG/fMRI neurofeedback
Description: EEG/fMRI neurofeedback
Study: NCT02345525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mCIMT
Description: This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hCIMT
Description: This intervention is based on 3 main aspects:~1. intensive training of functional tasks with the affected arm (massed practice)~2. constraint of the un-affected hand through a mitt~3. shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week).
Study: NCT02462954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ContraGel

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HEC Universal Placebo gel
Study: NCT00509548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG100801
Description: Eye drop, twice a day, 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG100801
Description: Eye drop, twice a day, 30 days.
Study: NCT06159933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine positioning
Description: According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early pronation
Description: According to our local protocol, starting from January 2022, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
Study: NCT00712010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein microgels
Description: Whey protein microgels versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein microgels
Description: Whey protein microgels versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein microgels
Description: Whey protein microgels versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein microgels
Description: Whey protein microgels versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein microgels
Description: Whey protein microgels versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein
Description: versus the six other arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed whey protein
Description: versus the six other arms
Study: NCT01373450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Liraglutide
Description: Single subcutaneous dose in the evening of the day before the GGI (Day-1)
Study: NCT03893201

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess quality of life
Study: NCT01139463

Intervention type: DRUG
Intervention: Haloperidol or olanzapine
Description: Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth